Pfizer unloads Colorado plant as it continues to hive off unwanted Hospira operations

Pfizer is selling a high-potentcy API facility in Boulder, Colorado, to CDMO CordenPharma, which already has a facility in that city.

Pfizer has sold another Hospira plant, its second in eight weeks, as it continues to whittle down the unwanted operations it picked up in its $15 billion buyout of the sterile drug manufacturer.  

CDMO CordenPharma says it has a deal to buy the Hospira high containment API facility in Boulder, Colorado. Corden will take on the 100 employees at the plant when the deal closes, which is expected in November.

The dollars and cents of the deal were not made public, but Corden said it has a multi-year supply arrangement with Pfizer that will help it cover costs of the operation over the next few years while it builds the business.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

RELATED: Pfizer closing Hospira plant in Colorado, 100 jobs to be lost

Pfizer last year said the Boulder site was underutilized and it would be closed by 2019 if a buyer couldn’t be found.

The 54,000-square-foot facility with more than 100 employees has API production capabilities ranging from small scale up to 3,000 liters. CordenPharma said the facility, which it bought to bolster its highly potent and oncology platform and supply services, will be integrated with another site in Boulder which Corden’s parent company, International Chemical Investors Group, bought from Roche in 2011.

RELATED: CDMO Avara snaps up former Hospira sterile plant from Pfizer

Hospira has been steadily paring down operations it doesn't need. The Boulder facility is the second Hospira plant Pfizer has agreed to sell in the last two months. In August, it reached a deal with CDMO Avara to sell its plant in Liscate, Italy. Avara took on the 250 employees that work there.

It also sold off Hospira's infusion pump and medical device businesses to ICU Medical for $1 billion last year and decided to close four Hospira logistics centers across the country and consolidate distribution into two Pfizer logistics centers. That move cost more than 100 workers their jobs.

Just ahead of its sale to Pfizer in 2015, Hospira closed a plant in North Carolina and laid off about 250 workers there. 

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.